Johnson & Johnson (NYSE:JNJ) is a stock on Jim Cramer’s radar this week. Cramer explained why he sold it for the Charitable Trust, citing the company’s focus on its pharma business and ongoing talc lawsuits. JNJ develops and sells healthcare products, including pharmaceuticals and medical technologies in various fields. While JNJ has potential as an investment, some believe AI stocks offer greater upside potential and less downside risk. For more insights on AI stocks, check out a free report on the best short-term AI stock.

Read more at Yahoo Finance: Jim Cramer Says He Was Wrong for Selling Johnson & Johnson for the Charitable Trust